Bristol Myers Squibb (BMY) reported $11.2 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 5.6%. EPS of $1.80 for the same period compares to -$4.40 a year ago.
The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $10.73 billion. With the consensus EPS estimate being $1.51, the EPS surprise was +19.21%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Bristol Myers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Abraxane- U.S. $40 million versus $66.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -72.4% change.
- Net Sales- Opdivo- U.S. $1.33 billion compared to the $1.19 billion average estimate based on four analysts. The reported number represents a change of +15.3% year over year.
- Net Sales- Pomalyst/Imnovid- U.S. $537 million versus $588.85 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change.
- Net Sales- Pomalyst/Imnovid- International: $122 million versus the four-analyst average estimate of $118.98 million. The reported number represents a year-over-year change of -54.5%.
- Net Sales- Revlimid: $936 million versus the five-analyst average estimate of $884.91 million. The reported number represents a year-over-year change of -43.9%.
- Net Sales- Opdivo: $2.27 billion versus the five-analyst average estimate of $2.17 billion. The reported number represents a year-over-year change of +9%.
- Net Sales- Abraxane: $105 million versus the five-analyst average estimate of $125.23 million. The reported number represents a year-over-year change of -51.6%.
- Net Sales- Reblozyl: $478 million versus the five-analyst average estimate of $477.54 million. The reported number represents a year-over-year change of +35%.
- Net Sales- Zeposia: $107 million versus the five-analyst average estimate of $119.29 million. The reported number represents a year-over-year change of -2.7%.
- Net Sales- Breyanzi: $263 million versus the five-analyst average estimate of $240.29 million. The reported number represents a year-over-year change of +145.8%.
- Net Sales- Abecma: $103 million versus $97.70 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +25.6% change.
- Net Sales- Opdualag: $252 million versus the five-analyst average estimate of $261.59 million. The reported number represents a year-over-year change of +22.3%.
View all Key Company Metrics for Bristol Myers here>>>
Shares of Bristol Myers have returned -18% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
